New drug ALXN2230 put to the test in healthy volunteers
NCT ID NCT07352423
First seen Feb 01, 2026 · Last updated May 01, 2026 · Updated 13 times
Summary
This early-stage study is testing a new drug, ALXN2230, in 48 healthy adults to see if it is safe and how the body processes it. Participants receive a single injection of either the drug or a placebo. The study tracks side effects, drug levels in the blood, and immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGLondon, NW10 7EW, United Kingdom
Conditions
Explore the condition pages connected to this study.